Sign Up for Email Alerts
Kineta Inc.
Kineta Inc.
Kineta Inc.
Close
  • About Us
    • company
    • team
    • board
    • SAB
  • pipeline
    • overview
    • KVA12123 (VISTA)
    • CD27
  • partnerships
  • investors
    • overview
    • press releases
    • events & presentations
    • stock information
    • analyst coverage
    • SEC filings
    • corporate governance
    • IRS Form 8937
  • careers
  • contact
  • en_USEnglish
    • ko_KRKorean
  • About Us
    • company
    • team
    • board
    • SAB
  • pipeline
    • overview
    • KVA12123 (VISTA)
    • CD27
  • partnerships
  • investors
    • overview
    • press releases
    • events & presentations
    • stock information
    • analyst coverage
    • SEC filings
    • corporate governance
    • IRS Form 8937
  • careers
  • contact
  • en_USEnglish
    • ko_KRKorean

[be_recent_posts_author_no_link title=”Latest News from Kineta” category_id=”4,3″ num_posts=”6″ post_offset=”0″ num_words_limit=”0″ show_date_author=”1″ show_more_link=”0″ more_link_text=”Read more” show_thumbs=”0″ remove_thumb_frame=”0″ thumb_frame_shadow=”0″ default_thumb=”0″ post_thumb_width=”100″ post_thumb_height=”80″]

Recent Kineta News

  • Interim results of the ongoing phase 1/2 clinical trial of KVA12123, an engineered IgG1 targeting VISTA, alone and in combination with pembrolizumab in advanced solid tumors
  • Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
  • Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
  • KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported
  • VISTA a potential new Immuno-oncology therapeutic target to treat human Acute Myeloid Leukemia
Post placeholder image
April 16, 2018 in Biotech Industry News

Kineta starts drug development collaboration with Genentech

Kineta Inc 4 Like Post Comments Off on Kineta starts drug development collaboration with Genentech
Read More
Post placeholder image
April 16, 2018 in Biotech Industry News

Kineta to Collaborate on the Development of a Novel Non-Opioid Pain Therapy with Genentech

Kineta Inc 4 Like Post Comments Off on Kineta to Collaborate on the Development of a Novel Non-Opioid Pain Therapy with Genentech
Read More
Post placeholder image
April 16, 2018 in Biotech Industry News

Seattle biotech Kineta teams up with Genentech to create chronic pain medicine

Kineta Inc 4 Like Post Comments Off on Seattle biotech Kineta teams up with Genentech to create chronic pain medicine
Read More
Post placeholder image
April 16, 2018 in Biotech Industry News

Kineta signs multi-million dollar collaboration with Genentech to develop non-opioid pain medication

Kineta Inc 4 Like Post Comments Off on Kineta signs multi-million dollar collaboration with Genentech to develop non-opioid pain medication
Read More
Post placeholder image
April 16, 2018 in Biotech Industry News

Kineta inks $360 million-plus deal with Genentech for chronic pain drug

Kineta Inc 3 Like Post Comments Off on Kineta inks $360 million-plus deal with Genentech for chronic pain drug
Read More
Post placeholder image
April 16, 2018 in Biotech Industry News

Roche partners with Kineta to develop non-opioid pain therapy

Kineta Inc 3 Like Post Comments Off on Roche partners with Kineta to develop non-opioid pain therapy
Read More
Post placeholder image
April 16, 2018 in Biotech Industry News

Genentech, Kineta to Partner on Non-Opioid Pain Treatments

Kineta Inc 3 Like Post Comments Off on Genentech, Kineta to Partner on Non-Opioid Pain Treatments
Read More
Post placeholder image
April 16, 2018 in Biotech Industry News

NAChR average pain drug, Kineta bid bags Genentech deal for as much as $359M+

Kineta Inc 3 Like Post Comments Off on NAChR average pain drug, Kineta bid bags Genentech deal for as much as $359M+
Read More
Post placeholder image
April 16, 2018 in Biotech Industry News

Kineta, Roche’s Genentech strike chronic pain deal

Kineta Inc 3 Like Post Comments Off on Kineta, Roche’s Genentech strike chronic pain deal
Read More
Post placeholder image
April 16, 2018 in Biotech Industry News

Kineta inks $360 million-plus deal with Genentech for chronic pain drug

Kineta Inc 3 Like Post Comments Off on Kineta inks $360 million-plus deal with Genentech for chronic pain drug
Read More
Prev12Next

219 Terry Ave. N. Suite 300. Seattle, WA 98109

Sign Up for Email Alerts

219 Terry Ave. N. Suite 300. Seattle, WA 98109

  • About Us
  • pipeline
  • partnerships
  • investors
  • contact
Sign Up for Email Alerts

© 2024 Kineta Inc. Privacy Policy Terms of Use

English
English
Korean